245 related articles for article (PubMed ID: 32942128)
1. Harnessing the bioresponsive adhesion of immuno-bioglue for enhanced local immune checkpoint blockade therapy.
Joo KI; Jeong Y; Hwang SM; Shin M; Lee J; Sharma G; Lee H; Im SH; Cha HJ
Biomaterials; 2020 Dec; 263():120380. PubMed ID: 32942128
[TBL] [Abstract][Full Text] [Related]
2. Nano-vaccines combining customized in situ anti-PD-L1 depot for enhanced tumor immunotherapy.
Chen Q; Sun M; Li Y; Huang L; Zu C; Kuang X; Zhao J; Hao M; Ma T; Li C; Tu J; Sun C; Du Y
Nanomedicine; 2023 Sep; 53():102693. PubMed ID: 37343780
[TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
4. A review of immune checkpoint blockade in breast cancer.
Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
[TBL] [Abstract][Full Text] [Related]
5. RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast Cancer.
Tentler JJ; Lang J; Capasso A; Kim DJ; Benaim E; Lee YB; Eisen A; Bagby SM; Hartman SJ; Yacob BW; Gittleman B; Pitts TM; Pelanda R; Eckhardt SG; Diamond JR
BMC Cancer; 2020 Nov; 20(1):1063. PubMed ID: 33148223
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive Testing of Chemotherapy and Immune Checkpoint Blockade in Preclinical Cancer Models Identifies Additive Combinations.
Principe N; Aston WJ; Hope DE; Tilsed CM; Fisher SA; Boon L; Dick IM; Chin WL; McDonnell AM; Nowak AK; Lake RA; Chee J; Lesterhuis WJ
Front Immunol; 2022; 13():872295. PubMed ID: 35634282
[TBL] [Abstract][Full Text] [Related]
7. Injectable Bioresponsive Gel Depot for Enhanced Immune Checkpoint Blockade.
Yu S; Wang C; Yu J; Wang J; Lu Y; Zhang Y; Zhang X; Hu Q; Sun W; He C; Chen X; Gu Z
Adv Mater; 2018 Jul; 30(28):e1801527. PubMed ID: 29786888
[TBL] [Abstract][Full Text] [Related]
8. Mechanistic Insights into Synergy between Melanin-Targeting Radioimmunotherapy and Immunotherapy in Experimental Melanoma.
Malo ME; Allen KJH; Jiao R; Frank C; Rickles D; Dadachova E
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218169
[TBL] [Abstract][Full Text] [Related]
9. Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy.
Yang P; Lu C; Qin W; Chen M; Quan G; Liu H; Wang L; Bai X; Pan X; Wu C
Acta Biomater; 2020 Mar; 104():147-157. PubMed ID: 31904558
[TBL] [Abstract][Full Text] [Related]
10. Combinational Immunotherapy for Hepatocellular Carcinoma: Radiotherapy, Immune Checkpoint Blockade and Beyond.
Lee YH; Tai D; Yip C; Choo SP; Chew V
Front Immunol; 2020; 11():568759. PubMed ID: 33117354
[TBL] [Abstract][Full Text] [Related]
11. Nanodrug with dual-sensitivity to tumor microenvironment for immuno-sonodynamic anti-cancer therapy.
Huang J; Xiao Z; An Y; Han S; Wu W; Wang Y; Guo Y; Shuai X
Biomaterials; 2021 Feb; 269():120636. PubMed ID: 33453632
[TBL] [Abstract][Full Text] [Related]
12. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
13. MIF inhibition as a strategy for overcoming resistance to immune checkpoint blockade therapy in melanoma.
de Azevedo RA; Shoshan E; Whang S; Markel G; Jaiswal AR; Liu A; Curran MA; Travassos LR; Bar-Eli M
Oncoimmunology; 2020 Dec; 9(1):1846915. PubMed ID: 33344042
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of anti-tumor efficacy of immune checkpoint blockade by alpha-TEA.
Redmond WL; Kasiewicz MJ; Akporiaye ET
Front Immunol; 2023; 14():1057702. PubMed ID: 36911733
[TBL] [Abstract][Full Text] [Related]
15. Anti-melanoma Effects of Resiquimod (RSQ) In Vitro and in Combination with Immune Checkpoint Blockade In Vivo.
Tambunlertchai S; Geary SM; Naguib YW; Salem AK
AAPS J; 2023 Jun; 25(4):57. PubMed ID: 37266761
[TBL] [Abstract][Full Text] [Related]
16. Targeting CXCL12-CXCR4 Signaling Enhances Immune Checkpoint Blockade Therapy Against Triple Negative Breast Cancer.
Lu G; Qiu Y; Su X
Eur J Pharm Sci; 2021 Feb; 157():105606. PubMed ID: 33131745
[TBL] [Abstract][Full Text] [Related]
17. Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade.
Li Q; Wang Y; Jia W; Deng H; Li G; Deng W; Chen J; Kim BYS; Jiang W; Liu Q; Liu J
Clin Cancer Res; 2020 Apr; 26(7):1712-1724. PubMed ID: 31848190
[TBL] [Abstract][Full Text] [Related]
18. High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade.
Chua KLM; Fehlings M; Yeo ELL; Nardin A; Sumatoh H; Chu PL; Nei WL; Ong EHW; Woo WY; Low KP; Wang H; Poon DJJ; Liang ZG; Yao K; Huang L; Toh CK; Ang MK; Farid M; Cheng XM; Kanesvaran R; Dent R; Wee JTS; Lim TKH; Iyer NG; Tan DSW; Soo KC; Newell EW; Chua MLK
Int J Radiat Oncol Biol Phys; 2020 Sep; 108(1):70-80. PubMed ID: 32544576
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of melanoma with immune checkpoints inhibitors].
Lupu J; Hamann P; Routier É; Robert C
Rev Prat; 2021 Apr; 71(4):380-383. PubMed ID: 34161002
[TBL] [Abstract][Full Text] [Related]
20. Combined Blockade of IL6 and PD-1/PD-L1 Signaling Abrogates Mutual Regulation of Their Immunosuppressive Effects in the Tumor Microenvironment.
Tsukamoto H; Fujieda K; Miyashita A; Fukushima S; Ikeda T; Kubo Y; Senju S; Ihn H; Nishimura Y; Oshiumi H
Cancer Res; 2018 Sep; 78(17):5011-5022. PubMed ID: 29967259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
